Investigational Drug Details
| Drug ID: | D390 |
| Drug Name: | VK-2809 |
| Synonyms: | MB-07811; VK 2809 |
| Type: | Chemical drug |
| DrugBank ID: | DB15137 |
| DrugBank Description: | VK-2809 is under investigation in clinical trial NCT02927184 (Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease). |
| PubChem ID: | 15942005 |
| CasNo: | 852948-13-1 |
| Repositioning for NAFLD: | No |
| SMILES: | C(Oc1cc(C)c(c(c1)C)Cc1cc(C(C)C)c(cc1)O)P1(=O)O[C@@H](CCO1)c1cc(Cl)ccc1 |
| Structure: |
|
| InChiKey: | LGGPZDRLTDGYSQ-GYKKGXIBSA-N |
| Molecular Weight: | 514.986 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | THR agonist |
| Therapeutic Category: | Anti-fibrosis |
| Clinical Trial Progress: | Phase 2 completed (NCT02927184) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title |
|---|